Medtronic (NYSE:MDT) has plans to submit its MiniMed 780G for an expanded indication from the FDA for type 2 diabetes in the near future.

Why it matters: Tandem hit choppy waters in 2022 and 2023 when rival Insulet rolled out its Omnipod 5 with automatic insulin delivery and Medtronic launched its 780g pump with meal time algorithms ...